CryoCell Research Development vs Total Other Income Expense Net Analysis

CCEL Stock

USD 5.87 0.03 0.51%

CryoCell International financial indicator trend analysis is way more than just evaluating CryoCell International prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CryoCell International is a good investment. Please check the relationship between CryoCell International Research Development and its Total Other Income Expense Net accounts. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

Research Development vs Total Other Income Expense Net

Research Development vs Total Other Income Expense Net Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CryoCell International Research Development account and Total Other Income Expense Net. At this time, the significance of the direction appears to have pay attention.

The correlation between CryoCell International's Research Development and Total Other Income Expense Net is -0.94. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of CryoCell International, assuming nothing else is changed. The correlation between historical values of CryoCell International's Research Development and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of CryoCell International are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Research Development i.e., CryoCell International's Research Development and Total Other Income Expense Net go up and down completely randomly.

Correlation Coefficient

-0.94

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Research Development

Total Other Income Expense Net

Most indicators from CryoCell International's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CryoCell International current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

The value of Selling General Administrative is expected to slide to about 11.2 M. Tax Provision is expected to rise to about (3.3 M) this year

	2021	2022	2023	2024 (projected)
Gross Profit	21.5M	22.9M	26.3M	27.7M
Total Revenue	30.3M	31.3M	36.0M	18.4M

Gross Profit Total Revenue

CryoCell International fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Other Current Assets	Short Term Debt	Short Term Investments	Common Stock	Other Liab	Other Assets
Total Assets		0.89	0.94	0.1	0.79	0.57	-0.03	0.74	-0.09	0.97	0.74	-0.05	0.88	-0.49	0.97	0.02	0.97	0.32	0.5	0.66	-0.21	0.61	-0.27	0.87	0.99	0.96
Other Current Liab	0.89		0.9	0.08	0.8	0.46	-0.14	0.79	-0.22	0.91	0.55	-0.21	0.73	-0.29	0.85	0.22	0.87	0.1	0.56	0.42	0.03	0.3	-0.15	0.8	0.88	0.76
Total Current Liabilities	0.94	0.9		-0.15	0.75	0.55	-0.29	0.83	-0.04	0.9	0.63	0.0	0.94	-0.33	0.95	0.18	0.97	0.35	0.41	0.66	-0.1	0.55	-0.12	0.89	0.96	0.89
Total Stockholder Equity	0.1	0.08	-0.15		-0.13	-0.45	0.78	-0.42	0.24	0.12	0.39	0.19	-0.28	-0.17	-0.13	-0.2	-0.13	-0.05	0.6	-0.4	-0.05	0.08	-0.38	-0.08	0.01	0.07
Property Plant And Equipment Net	0.79	0.8	0.75	-0.13		0.74	-0.2	0.9	-0.63	0.87	0.39	-0.6	0.69	-0.34	0.85	0.16	0.83	-0.16	0.15	0.51	-0.06	0.12	-0.13	0.66	0.8	0.67
Net Debt	0.57	0.46	0.55	-0.45	0.74		-0.28	0.69	-0.63	0.59	0.12	-0.58	0.57	-0.4	0.71	-0.08	0.67	0.02	0.0	0.84	-0.17	0.3	0.01	0.53	0.58	0.56
Retained Earnings	-0.03	-0.14	-0.29	0.78	-0.2	-0.28		-0.44	0.23	-0.01	0.22	0.21	-0.35	-0.6	-0.18	-0.75	-0.21	-0.07	0.29	-0.18	-0.38	0.25	-0.5	-0.19	-0.13	0.05
Accounts Payable	0.74	0.79	0.83	-0.42	0.9	0.69	-0.44		-0.46	0.78	0.28	-0.41	0.78	-0.27	0.84	0.2	0.85	-0.01	0.0	0.55	-0.04	0.14	0.02	0.7	0.78	0.65
Cash	-0.09	-0.22	-0.04	0.24	-0.63	-0.63	0.23	-0.46		-0.26	0.27	0.99	0.03	-0.03	-0.2	-0.19	-0.16	0.63	0.17	-0.12	-0.15	0.5	-0.14	-0.03	-0.09	0.07
Non Current Assets Total	0.97	0.91	0.9	0.12	0.87	0.59	-0.01	0.78	-0.26		0.72	-0.23	0.81	-0.45	0.94	0.04	0.94	0.07	0.5	0.57	-0.18	0.46	-0.3	0.83	0.96	0.88
Non Currrent Assets Other	0.74	0.55	0.63	0.39	0.39	0.12	0.22	0.28	0.27	0.72		0.28	0.63	-0.3	0.63	-0.04	0.64	0.22	0.53	0.34	-0.14	0.66	-0.27	0.62	0.73	0.75
Cash And Short Term Investments	-0.05	-0.21	0.0	0.19	-0.6	-0.58	0.21	-0.41	0.99	-0.23	0.28		0.08	-0.08	-0.15	-0.22	-0.11	0.68	0.13	-0.05	-0.2	0.54	-0.13	0.01	-0.05	0.12
Net Receivables	0.88	0.73	0.94	-0.28	0.69	0.57	-0.35	0.78	0.03	0.81	0.63	0.08		-0.34	0.93	0.16	0.94	0.46	0.21	0.75	-0.17	0.64	-0.12	0.84	0.93	0.89
Common Stock Shares Outstanding	-0.49	-0.29	-0.33	-0.17	-0.34	-0.4	-0.6	-0.27	-0.03	-0.45	-0.3	-0.08	-0.34		-0.48	0.8	-0.45	-0.24	-0.13	-0.55	0.65	-0.63	0.54	-0.36	-0.43	-0.62
Non Current Liabilities Total	0.97	0.85	0.95	-0.13	0.85	0.71	-0.18	0.84	-0.2	0.94	0.63	-0.15	0.93	-0.48		0.04	1.0	0.3	0.32	0.76	-0.22	0.58	-0.2	0.87	0.98	0.94
Other Stockholder Equity	0.02	0.22	0.18	-0.2	0.16	-0.08	-0.75	0.2	-0.19	0.04	-0.04	-0.22	0.16	0.8	0.04		0.08	-0.07	0.05	-0.25	0.61	-0.44	0.42	0.14	0.1	-0.16
Total Liab	0.97	0.87	0.97	-0.13	0.83	0.67	-0.21	0.85	-0.16	0.94	0.64	-0.11	0.94	-0.45	1.0	0.08		0.32	0.35	0.74	-0.19	0.57	-0.18	0.88	0.99	0.94
Total Current Assets	0.32	0.1	0.35	-0.05	-0.16	0.02	-0.07	-0.01	0.63	0.07	0.22	0.68	0.46	-0.24	0.3	-0.07	0.32		0.11	0.47	-0.16	0.68	0.04	0.35	0.32	0.49
Intangible Assets	0.5	0.56	0.41	0.6	0.15	0.0	0.29	0.0	0.17	0.5	0.53	0.13	0.21	-0.13	0.32	0.05	0.35	0.11		0.12	-0.03	0.35	-0.36	0.42	0.44	0.41
Short Long Term Debt Total	0.66	0.42	0.66	-0.4	0.51	0.84	-0.18	0.55	-0.12	0.57	0.34	-0.05	0.75	-0.55	0.76	-0.25	0.74	0.47	0.12		-0.33	0.73	-0.09	0.65	0.68	0.76
Other Current Assets	-0.21	0.03	-0.1	-0.05	-0.06	-0.17	-0.38	-0.04	-0.15	-0.18	-0.14	-0.2	-0.17	0.65	-0.22	0.61	-0.19	-0.16	-0.03	-0.33		-0.41	0.83	-0.19	-0.19	-0.33
Short Term Debt	0.61	0.3	0.55	0.08	0.12	0.3	0.25	0.14	0.5	0.46	0.66	0.54	0.64	-0.63	0.58	-0.44	0.57	0.68	0.35	0.73	-0.41		-0.3	0.57	0.6	0.78
Short Term Investments	-0.27	-0.15	-0.12	-0.38	-0.13	0.01	-0.5	0.02	-0.14	-0.3	-0.27	-0.13	-0.12	0.54	-0.2	0.42	-0.18	0.04	-0.36	-0.09	0.83	-0.3		-0.2	-0.23	-0.29
Common Stock	0.87	0.8	0.89	-0.08	0.66	0.53	-0.19	0.7	-0.03	0.83	0.62	0.01	0.84	-0.36	0.87	0.14	0.88	0.35	0.42	0.65	-0.19	0.57	-0.2		0.89	0.84
Other Liab	0.99	0.88	0.96	0.01	0.8	0.58	-0.13	0.78	-0.09	0.96	0.73	-0.05	0.93	-0.43	0.98	0.1	0.99	0.32	0.44	0.68	-0.19	0.6	-0.23	0.89		0.95
Other Assets	0.96	0.76	0.89	0.07	0.67	0.56	0.05	0.65	0.07	0.88	0.75	0.12	0.89	-0.62	0.94	-0.16	0.94	0.49	0.41	0.76	-0.33	0.78	-0.29	0.84	0.95

Click cells to compare fundamentals

CryoCell International Account Relationship Matchups

CryoCell International fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	46.2M	60.7M	64.9M	61.2M	70.4M	73.9M
Other Current Liab	2.9M	8.0M	5.6M	6.4M	7.3M	7.7M
Total Current Liabilities	16.4M	21.1M	19.5M	20.9M	24.0M	25.2M
Total Stockholder Equity	(2.7M)	4.2M	(1.5M)	(11.0M)	(9.9M)	(9.4M)
Property Plant And Equipment Net	1.9M	4.1M	14.2M	22.0M	25.3M	26.6M
Net Debt	(4.1M)	(5.4M)	9.9M	10.5M	9.4M	9.0M
Retained Earnings	(18.8M)	(16.7M)	(21.6M)	(31.2M)	(28.0M)	(29.4M)
Accounts Payable	957.4K	1.5M	1.6M	3.2M	3.7M	3.8M
Cash	10.4M	8.3M	1.7M	406.1K	467.0K	443.6K
Non Current Assets Total	27.6M	44.9M	55.3M	51.8M	59.5M	62.5M
Non Currrent Assets Other	11.6M	10.3M	9.9M	6.0M	6.9M	7.3M
Cash And Short Term Investments	10.4M	8.3M	1.7M	980.3K	1.1M	1.1M
Net Receivables	6.3M	5.3M	6.0M	6.6M	7.6M	7.9M
Common Stock Shares Outstanding	8.1M	8.4M	8.5M	8.3M	7.5M	7.8M
Liabilities And Stockholders Equity	46.2M	60.7M	64.9M	61.2M	70.4M	73.9M
Non Current Liabilities Total	32.5M	35.4M	46.9M	51.4M	59.1M	62.1M
Other Stockholder Equity	16.0M	20.8M	20.0M	20.0M	23.0M	21.5M
Total Liab	48.9M	56.5M	66.4M	72.3M	83.1M	87.2M
Total Current Assets	18.6M	15.8M	9.6M	9.5M	10.9M	10.5M
Intangible Assets	1.5M	16.2M	15.2M	989.1K	1.1M	2.0M
Short Long Term Debt Total	6.2M	2.8M	11.6M	10.9M	9.8M	9.3M
Other Current Assets	244.7K	711.2K	426.9K	390.0K	448.4K	770.9K
Short Term Debt	3.4M	2.2M	2.7M	1.6M	1.9M	1.6M
Short Term Investments	88.5K	75.4K	17.6K	574.2K	516.8K	641.7K
Common Stock	136.3K	146.7K	148.5K	148.5K	170.8K	134.7K
Other Liab	28.6M	29.6M	34.8M	38.0M	43.7M	45.9M
Other Assets	22.2M	21.9M	22.3M	23.7M	27.2M	28.6M
Long Term Debt	5.9M	2.8M	8.6M	8.4M	9.7M	5.2M
Property Plant Equipment	1.8M	1.6M	4.1M	14.2M	16.3M	17.2M
Current Deferred Revenue	9.2M	9.4M	9.6M	9.7M	11.2M	6.4M
Net Tangible Assets	(10.1M)	(2.7M)	(14.0M)	(18.6M)	(16.8M)	(17.6M)
Non Current Liabilities Other	32.5M	3.5M	2.0M	919.2K	827.3K	785.9K
Inventory	927.3K	921.2K	851.2K	768.9K	692.0K	657.4K

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as CryoCell International using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

Additional Information and Resources on Investing in CryoCell Stock

When determining whether CryoCell International is a strong investment it is important to analyze CryoCell International's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CryoCell International's future performance. For an informed investment choice regarding CryoCell Stock, refer to the following important reports:

How To Invest In CryoCell

Details

Is CryoCell Stock a good investment?

Details

What is CryoCell International's Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.25)

Earnings Share

(1.16)

Revenue Per Share

3.783

Quarterly Revenue Growth

0.004

Return On Assets

(0.01)

The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CryoCell Research Development vs Total Other Income Expense Net Analysis

Research Development vs Total Other Income Expense Net

Research Development vs Total Other Income Expense Net Correlation Analysis

Correlation Coefficient

Research Development

Total Other Income Expense Net

CryoCell International fundamental ratios Correlations

CryoCell International Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CryoCell International fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Additional Information and Resources on Investing in CryoCell Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Other Liab	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash
Other Liab	+ 0.99	Total Liab
Other Liab	+ 0.98	Non Current Liabilities Total
Non Current Assets Total	+ 0.97	Total Assets

Other Stockholder Equity	- 0.75	Retained Earnings
Short Term Debt	- 0.63	Common Stock Shares Outstanding
Cash	- 0.63	Net Debt
Cash	- 0.63	Property Plant And Equipment Net
Other Assets	- 0.62	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.6	Retained Earnings